Phase I/II Study of Adaptive Manufactured Lentiviral Anti-CD20/Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed, Refractory Mantle Cell Lymphoma
Journal of Clinical Oncology · 2025
DOI: 10.1200/jco-24-02158 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Journal of Clinical Oncology, 2025. Verfasst von Nirav N Shah und 18 weiteren Autor:innen. Beteiligte Einrichtung: BMT & Cellular Therapy Program, Division of Hematology & Oncology, Medical College of Wisconsin, Milwaukee, WI. Hauptthemen laut MEDLINE: Lymphoma, Mantle-Cell, Immunotherapy, Adoptive, Receptors, Chimeric Antigen, Antigens, CD19. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 26 Literaturangaben.
Abstract (Originalsprache)
PURPOSE Mantle cell lymphoma (MCL) is an aggressive B-cell malignancy characterized by t(11;14) and bright CD20 expression. To improve outcomes from single targeted CD19 chimeric antigen receptor (CAR) T cells, we used dual targeted lentiviral anti-CD20/anti-CD19 (LV20.19) CAR T cells as part of a phase I/II clinical trial in relapsed, refractory (R/R) MCL (ClinicalTrials.gov identifier: NCT04186520 ). METHODS Patients with MCL who had failed two lines of therapy or relapsed post-transplant were eligible. LV20.19 CAR T cells were manufactured on-site via CliniMACS Prodigy using an adaptive 8- to 12-day process to optimize the final CAR product for increased numbers of naïve and stem-cell memory (SCM) like T cells. RESULTS Seventeen patients with R/R MCL received a single dose of LV20.19 CAR T cells at 2.5 × 10 6 cells/kg (phase I = three patients; phase II = 14 patients). The best overall response rate (ORR) was 100% (complete response [CR] = 88%; partial response = 12%) and the phase II efficacy threshold for day-90 CR rate was exceeded. Two patients have relapsed as of the data cutoff and neither the median progression-free survival nor overall survival has been reached with a median follow-up of 15.8 months. Ninety-four percent (n = 16) experienced cytokine release syndrome, all grade 1-2. Eighteen percent (n = 3) had immune effector cell–associated neurotoxicity syndrome in the first 28-days, two with reversible grade 3 toxicity. Three patients had nonrelapse mortality events; all occurred in the setting of ongoing B-cell aplasia. The final LV20.19 CAR products were enriched for higher percentages of T- SCM /T-naïve cells and most patients received CAR T cells within 8 days of apheresis. CONCLUSION In conclusion, we demonstrate that on-site adaptive manufactured LV20.19 CAR T cells are feasible, safe, and efficacious for R/R MCL with best ORR of 100%, a favorable safety profile, and few relapses to date.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- BMT & Cellular Therapy Program, Division of Hematology & Oncology, Medical College of Wisconsin, Milwaukee, WI.
- Department of Microbiology & Immunology, Medical College of Wisconsin, Milwaukee, WI.
- Division of Biostatistics, Medical College of Wisconsin, Milwaukee, WI.
- Lentigen Technology Inc, a Miltenyi Biotec Company, Gaithersburg, MD.
- Division of Hematology & Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI.
- Department of Radiology, Medical College of Wisconsin, Milwaukee, WI.
ORCID-Profile: Nirav N Shah, Alfredo S Colina, Tyce Kearl, Dina Schneider, Marlenny Vargas-Cortes, Jessica L Schmeling, Peiman Hematti, Anthony E Zamora, Parameswaran Hari, Mehdi Hamadani, Timothy S Fenske
Zitieren
APA
Shah, N. N., Colina, A. S., Johnson, B. D., Szabo, A., Furqan, F., Kearl, T., Schneider, D., Vargas-Cortes, M., Schmeling, J. L., Dwinell, M. B., Palen, K., Longo, W., Hematti, P., Zamora, A. E., Hari, P., Bucklan, D., Cunningham, A., Hamadani, M., & Fenske, T. S. (2025). Phase I/II Study of Adaptive Manufactured Lentiviral Anti-CD20/Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed, Refractory Mantle Cell Lymphoma. Journal of Clinical Oncology. https://doi.org/10.1200/jco-24-02158
Vancouver
Shah NN, Colina AS, Johnson BD, Szabo A, Furqan F, Kearl T, et al. Phase I/II Study of Adaptive Manufactured Lentiviral Anti-CD20/Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed, Refractory Mantle Cell Lymphoma. Journal of Clinical Oncology. 2025. doi:10.1200/jco-24-02158
BibTeX
@article{Shah2025,
author = {Shah, Nirav N and Colina, Alfredo S and Johnson, Bryon D and Szabo, Aniko and Furqan, Fateeha and Kearl, Tyce and Schneider, Dina and Vargas-Cortes, Marlenny and Schmeling, Jessica L and Dwinell, Michael B and Palen, Katie and Longo, Walter and Hematti, Peiman and Zamora, Anthony E and Hari, Parameswaran and Bucklan, Daniel and Cunningham, Ashley and Hamadani, Mehdi and Fenske, Timothy S},
title = {Phase I/II Study of Adaptive Manufactured Lentiviral Anti-CD20/Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed, Refractory Mantle Cell Lymphoma},
journal = {Journal of Clinical Oncology},
year = {2025},
doi = {10.1200/jco-24-02158}
}
EUVIMED